These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9713494)

  • 1. Multidrug resistance related genes and p53 expression in human non small cell lung cancer.
    Galimberti S; Marchetti A; Buttitta F; Carnicelli V; Pellegrini S; Bevilacqua G; Petrini M
    Anticancer Res; 1998; 18(4C):2973-6. PubMed ID: 9713494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
    Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
    Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of MDR1, LRP, MRP, and topoisomerase IIalpha gene mRNA transcripts before and after interferon-alpha, and correlation with the mRNA expression level of the telomerase subunits hTERT and TEP1 in five unselected human melanoma cell lines.
    Miracco C; Maellaro E; Pacenti L; Del Bello B; Valentini MA; Rubegni P; Pirtoli L; Volpi C; Santopietro R; Tosi P
    Int J Oncol; 2003 Jul; 23(1):213-20. PubMed ID: 12792796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay.
    Withoff S; Smit EF; Meersma GJ; van den Berg A; Timmer-Bosscha H; Kok K; Postmus PE; Mulder NH; de Vries EG; Buys CH
    Lab Invest; 1994 Jul; 71(1):61-6. PubMed ID: 8041119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
    Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
    Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Y box-binding protein-1 correlates with DNA topoisomerase IIalpha and proliferating cell nuclear antigen expression in lung cancer.
    Gu C; Oyama T; Osaki T; Kohno K; Yasumoto K
    Anticancer Res; 2001; 21(4A):2357-62. PubMed ID: 11724293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of multidrug resistance gene expression levels with malignant potentials and influence of chemotherapy in urothelial cancers.
    Kakehi Y; Wu WJ; Kim WJ; Arao S; Fukumoto M; Yoshida O
    Int J Urol; 1995 Nov; 2(5):309-15. PubMed ID: 8749949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer.
    Campling BG; Young LC; Baer KA; Lam YM; Deeley RG; Cole SP; Gerlach JH
    Clin Cancer Res; 1997 Jan; 3(1):115-22. PubMed ID: 9815546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer.
    Boldrini L; Faviana P; Pistolesi F; Gisfredi S; Di Quirico D; Lucchi M; Mussi A; Angeletti CA; Baldinotti F; Fogli A; Simi P; Basolo F; Fontanini G
    Oncogene; 2001 Oct; 20(45):6632-7. PubMed ID: 11641789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
    Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
    Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density.
    Fontanini G; Boldrini L; Calcinai A; Chinè S; Lucchi M; Mussi A; Angeletti CA; Basolo F; Bevilacqua G
    Clin Cancer Res; 1999 Jan; 5(1):155-61. PubMed ID: 9918214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In situ detection of unexpected patterns of mutant p53 gene expression in non-small cell lung cancers.
    Ebina M; Martínez A; Birrer MJ; Ilona Linnoila R
    Oncogene; 2001 May; 20(20):2579-86. PubMed ID: 11420668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
    Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
    Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
    Gorgoulis VG; Zacharatos P; Mariatos G; Liloglou T; Kokotas S; Kastrinakis N; Kotsinas A; Athanasiou A; Foukas P; Zoumpourlis V; Kletsas D; Ikonomopoulos J; Asimacopoulos PJ; Kittas C; Field JK
    Cancer Res; 2001 Jan; 61(2):538-49. PubMed ID: 11212247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity.
    Mao Y; Yu C; Hsieh TS; Nitiss JL; Liu AA; Wang H; Liu LF
    Biochemistry; 1999 Aug; 38(33):10793-800. PubMed ID: 10451375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis.
    Takahashi T; Munakata M; Ohtsuka Y; Nisihara H; Nasuhara Y; Kamachi-Satoh A; Dosaka-Akita H; Homma Y; Kawakami Y
    Cancer; 2002 Aug; 95(3):624-33. PubMed ID: 12209756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced ING1b gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients.
    Kameyama K; Huang CL; Liu D; Masuya D; Nakashima T; Sumitomo S; Takami Y; Kinoshita M; Yokomise H
    Clin Cancer Res; 2003 Oct; 9(13):4926-34. PubMed ID: 14581367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy.
    Chevillard S; Lebeau J; Pouillart P; de Toma C; Beldjord C; Asselain B; Klijanienko J; Fourquet A; Magdelénat H; Vielh P
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2471-8. PubMed ID: 9815649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Reversal of multidrug resistance of human hepatocellular carcinoma cells by wild-type p53 gene and related mechanisms].
    Gai XD; Li GL; Huang JZ; Xue HJ; Wang D
    Ai Zheng; 2006 Aug; 25(8):954-9. PubMed ID: 16965674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a polymerase chain reaction aided transcript titration assay (PATTY) for topoisomerase II in lung cancer samples.
    Dingemans AM; Van Ark-Otte J; Smit EF; Postmus PE; Giaccone G
    Anticancer Res; 2000; 20(5B):3549-54. PubMed ID: 11131661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.